Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ACELYRIN, INC. - Common Stock (NQ:SLRN)

2.580 +0.110 (+4.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,599,517
Open 2.500
Bid (Size) 2.320 (50)
Ask (Size) 2.580 (14)
Prev. Close 2.470
Today's Range 2.450 - 2.655
52wk Range 1.845 - 7.250
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
From ACELYRIN, INC.
Via GlobeNewswire
Alumis and ACELYRIN Announce Amended Merger Agreement
From ACELYRIN, INC.
Via GlobeNewswire

Performance

YTD
-21.8%
-21.8%
1 Month
+2.8%
+2.8%
3 Month
+30.3%
+30.3%
6 Month
-54.6%
-54.6%
1 Year
-39.3%
-39.3%

More News

Read More
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
From Kahn Swick & Foti, LLC
Via Business Wire
3 Biopharmaceutical Stocks Bucking the Sell-Off
Via MarketBeat
Topics World Trade
Exposures Product Safety Tariff
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, SLRN, AKYA, SHYF on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
From ACELYRIN, INC.
Via GlobeNewswire
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week
Via Stocktwits
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, TGI, PTMN, SLRN on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
These stocks are moving in today's pre-market session
Via Chartmill
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
From ACELYRIN, INC.
Via GlobeNewswire
Wondering what's happening in today's after-hours session?
Via Chartmill
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IPG, SLRN, PTMN, HEES on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PLYA, SLRN, NVRO, AMPS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, TGI, PTMN on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Shareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public Shareholders
From Ademi & Fruchter LLP
Via Business Wire
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
From ACELYRIN, INC.
Via GlobeNewswire
Nasdaq Down 1.5%; RPM Posts Upbeat Results
Via Benzinga
Dow Surges Over 100 Points; US Trade Deficit Widens In November
Via Benzinga
Topics Stocks
Exposures US Equities
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
From ACELYRIN, INC.
Via GlobeNewswire

Frequently Asked Questions

Is ACELYRIN, INC. - Common Stock publicly traded?
Yes, ACELYRIN, INC. - Common Stock is publicly traded.
What exchange does ACELYRIN, INC. - Common Stock trade on?
ACELYRIN, INC. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ACELYRIN, INC. - Common Stock?
The ticker symbol for ACELYRIN, INC. - Common Stock is SLRN on the Nasdaq Stock Market
What is the current price of ACELYRIN, INC. - Common Stock?
The current price of ACELYRIN, INC. - Common Stock is 2.580
When was ACELYRIN, INC. - Common Stock last traded?
The last trade of ACELYRIN, INC. - Common Stock was at 05/01/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.